PURPOSE: Intimal hyperplasia (IH), a well-recognized cause of dialysis vascular access failure, is generally believed to be an acquired pathologic lesion. Recent data suggests that IH is present prior to AVF creation. We sought to determine whether pre-existing inflammation and oxidation co-exist with IH prior to their incorporation into an AVF conduit, as their presence may predispose the AVF to further IH following AVF creation. METHODS: At the time of first AV access surgery, vein segments were collected from ten Stage 4 and 5 CKD patients undergoing AVF creation 6-12 months prior to anticipated dialysis initiation. Morphometry and immunohistochemistry was performed to detect inflammatory markers IL-6, TGF-ß1, and TNFa, and markers of DNA oxidative damage (8-Hydroxy-2'-deoxyguanosine [HNE]) and lipid peroxidation (4-Hydroxy-2-Nonenal [8OHdG]). RESULTS: The degree of IH severity was variable. IL-6, TGF-ß1, and TNFa co-localized with a-smooth muscle actin prominently within the venous intima and media. Although more diffuse, HNE and 8OHdG were intensely expressed in parallel with the inflammatory markers. In spite of these findings, however, neither extant IH nor the intensity of inflammatory or oxidative markers were associated with primary or secondary AVF failure at 12 month follow-up. CONCLUSIONS: Not only does venous IH pre-exist, but inflammation and oxidation markers are present within veins used for the AVF conduit prior to its creation in CKD patients as early as one year before dialysis is commenced. Nevertheless, short and long-term AVF outcomes were not associated with the inflammatory or oxidative burden, suggesting the complexity of AVF dysfunction in humans with CKD.
PURPOSE: Intimal hyperplasia (IH), a well-recognized cause of dialysis vascular access failure, is generally believed to be an acquired pathologic lesion. Recent data suggests that IH is present prior to AVF creation. We sought to determine whether pre-existing inflammation and oxidation co-exist with IH prior to their incorporation into an AVF conduit, as their presence may predispose the AVF to further IH following AVF creation. METHODS: At the time of first AV access surgery, vein segments were collected from ten Stage 4 and 5 CKDpatients undergoing AVF creation 6-12 months prior to anticipated dialysis initiation. Morphometry and immunohistochemistry was performed to detect inflammatory markers IL-6, TGF-ß1, and TNFa, and markers of DNA oxidative damage (8-Hydroxy-2'-deoxyguanosine [HNE]) and lipid peroxidation (4-Hydroxy-2-Nonenal [8OHdG]). RESULTS: The degree of IH severity was variable. IL-6, TGF-ß1, and TNFa co-localized with a-smooth muscle actin prominently within the venous intima and media. Although more diffuse, HNE and 8OHdG were intensely expressed in parallel with the inflammatory markers. In spite of these findings, however, neither extant IH nor the intensity of inflammatory or oxidative markers were associated with primary or secondary AVF failure at 12 month follow-up. CONCLUSIONS: Not only does venous IH pre-exist, but inflammation and oxidation markers are present within veins used for the AVF conduit prior to its creation in CKDpatients as early as one year before dialysis is commenced. Nevertheless, short and long-term AVF outcomes were not associated with the inflammatory or oxidative burden, suggesting the complexity of AVF dysfunction in humans with CKD.
Authors: P Roy-Chaudhury; B S Kelly; M A Miller; A Reaves; J Armstrong; N Nanayakkara; S C Heffelfinger Journal: Kidney Int Date: 2001-06 Impact factor: 10.612
Authors: Alexander S Yevzlin; Emily L Conley; Robert J Sanchez; Henry N Young; Bryan N Becker Journal: Semin Dial Date: 2006 Nov-Dec Impact factor: 3.455
Authors: Daniela Marrone; Giovanni Pertosa; Simona Simone; Antonella Loverre; Carmen Capobianco; Mario Cifarelli; Bruno Memoli; Francesco P Schena; Giuseppe Grandaliano Journal: Am J Kidney Dis Date: 2007-05 Impact factor: 8.860
Authors: Lucas M Ferrer; Alexandra M Monroy; Jahaira Lopez-Pastrana; Gayani Nanayakkara; Ramon Cueto; Ya-Feng Li; Xinyuan Li; Hong Wang; Xiao-Feng Yang; Eric T Choi Journal: J Cardiovasc Transl Res Date: 2016-02-29 Impact factor: 4.132
Authors: Karen C Chong; Christopher D Owens; Meyeon Park; Hugh F Alley; W John Boscardin; Michael S Conte; Warren J Gasper; S Marlene Grenon Journal: J Vasc Surg Date: 2014-10-16 Impact factor: 4.268
Authors: Charles E Alpers; Peter B Imrey; Kelly L Hudkins; Tomasz A Wietecha; Milena Radeva; Michael Allon; Alfred K Cheung; Laura M Dember; Prabir Roy-Chaudhury; Yan-Ting Shiu; Christi M Terry; Alik Farber; Gerald J Beck; Harold I Feldman; John W Kusek; Jonathan Himmelfarb Journal: J Am Soc Nephrol Date: 2017-07-19 Impact factor: 10.121
Authors: Joy P Walker; Jade S Hiramoto; Warren J Gasper; Philip Auyang; Michael S Conte; Joseph H Rapp; David H Lovett; Christopher D Owens Journal: J Vasc Surg Date: 2014-02-28 Impact factor: 4.268